Ondansetron

Also known as: Zofran, ODT

Status

FDA-approved. Approved for prevention of nausea and vomiting from chemotherapy, radiotherapy and surgery. Use during GLP-1 titration is off-label and is a prescriber's decision. The 32 mg single intravenous dose was withdrawn over QT prolongation.

What it is

A prescription anti-nausea medicine, commonly the one prescribers reach for during incretin titration.

What published research measured

A selective serotonin 5-HT3 receptor antagonist, well established for chemotherapy and post-operative nausea. It appears in this library because nausea is the most common reason people stop incretin therapy, and this is a frequently prescribed answer to it. Two things are worth knowing: it prolongs the QT interval, and it is constipating — which compounds an effect incretins already produce. It does not treat the cause of incretin nausea, which is delayed gastric emptying.

Source

Apfel CC et al. 2004 — A factorial trial of six interventions for the prevention of postoperative nausea and vomiting · Schinkel AH et al. 1996 — P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of ma… · Gershon MD et al. 2007 — The serotonin signaling system: from basic understanding to drug development for functional GI disorders

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.